Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.
about
Does my patient with a serum monoclonal spike have multiple myeloma?Smoldering multiple myelomaImaging of multiple myeloma: Current conceptsSmoldering multiple myeloma.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathyLong-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myelomaEarly versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trialsA single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myelomaHigh levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaClinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.FDG-PET imaging in hematological malignanciesKinase inhibitors as potential agents in the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.New approaches to smoldering myeloma.An old drug with a new future: bendamustine in multiple myeloma.Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.Management of asymptomatic myeloma patients.V. Smoldering multiple myeloma.MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.Haematological cancer: Treatment of smoldering multiple myeloma.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.B-Cell Disorders and Curcumin.Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
P2860
Q26821981-5A2BD9EE-2264-4BA6-97C0-D0447B48EAF2Q26863331-551A2CDB-BDE6-4538-96C5-D3E982D3C471Q26864616-1713A47E-8BB6-4101-AB65-BC20D59B54B1Q28082855-038C59C3-F7D6-4973-91E2-752B70CA6FFEQ34075717-8E04957D-3663-4B37-8624-B0B121E18086Q34370957-A7B5C24A-9304-435E-811F-AEA0DD930C81Q34497797-03159775-5C00-4831-8085-0D29771F8527Q35298727-8EEBB619-4AB7-4281-A7F6-F26590FE3620Q36270127-EF79D0B2-EEE5-4BE4-95B1-18DE0328A36BQ36683750-7C185205-B262-498F-B57B-2FB21ED46DF6Q37057028-7DF574B1-8664-4B7D-82AE-E2E56483205DQ37171994-FB3BCA6D-BB14-4B26-89C8-94AE78C46977Q37429722-645D57EC-CA05-4CBC-9788-D8DD9435DE1EQ37550846-A80F6B34-2DD5-40C7-85A1-2A52EC376559Q37632114-4681B84C-EA3F-41AE-8A61-12108E3E2D1EQ37697253-9E486A3D-402D-42C3-9980-F0DE8C64EC28Q38037600-333BB7A9-CB93-46EE-BF3C-6792836D990FQ38108391-83373A61-67AF-4F79-81D2-B20A54EFCD7EQ38131457-92C621C0-A062-4487-90F7-65EB6D12028CQ38139989-651A9923-C336-4CE5-A3F9-30E699B32BDEQ38202605-5E0D40F3-844C-44F9-95B3-E65AF4DD57D5Q38264322-5494EF38-5586-4D39-B99E-2D615948F187Q38523976-5D17089A-580A-4031-A99C-51692A7C6552Q38970567-92722C92-1F39-4481-9B5D-D978A97992B5Q40787161-1B3B9903-0B84-4E5D-AA0A-BDBB715A0C06Q42250752-F46BE67E-2829-488B-A50D-BB7D38DFB95EQ44869224-CE14F9AA-A553-4488-A503-A901901AB13BQ45965429-022FBC17-901A-4331-9509-9F0CA676D412Q47642719-3B64060A-241E-42D2-AA14-0D64C7BA982DQ49773570-E866E612-27AD-4F48-A0F3-89F53DAEB407Q53093363-12753DEB-41B8-4A68-95D0-B75B4EED6174Q59135626-73E3AD18-E8E1-43CA-A9B8-39E7044E0ECF
P2860
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@ast
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@en
type
label
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@ast
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@en
prefLabel
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@ast
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@en
P2860
P50
P356
P1476
Smoldering (asymptomatic) mult ...... and follow-up recommendations.
@en
P2093
Joan Bladé
Laura Rosiñol
P2860
P304
P356
10.1200/JCO.2009.22.2257
P407
P577
2009-12-21T00:00:00Z